The TRANSVAC2 success story has been published online on European Commission website.
To date, 80 % of all vaccines have been produced in Europe. TRANSVAC2 will create the network necessary to ensure Europe maintains and expands its international competitive edge.
This will be achieved by optimising the workflow for vaccine development through European universities, research institutes, innovative start-ups and large biomedical enterprises.
Read the full article on http://ec.europa.eu/research/infocentre/article_en.cfm?&artid=49836&caller=FP